Pharmacologic management of weight regain following bariatric surgery

Front Endocrinol (Lausanne). 2023 Jan 9:13:1043595. doi: 10.3389/fendo.2022.1043595. eCollection 2022.

Abstract

While bariatric surgery restults in significant long-term weight loss for most patients with obesity, post-surgical weight gain affects a considerable percentage of patients to varying degrees of severity. Furthermore, a small but significant percentage of patients experience inadequate post-surgical weight loss. Although many studies have examined the role of anti-obesity medications to address post-operative weight regain, an evidence-based consensus has not yet been achieved because of the heterogeneity of populations studied and the studies themselves. Observational studies in the post-bariatric surgery population consistently demonstrate the benefit of medical weight management after bariatric surgery, with most evidence highlighting liraglutide, topiramate, and phentermine/topiramate. New anti-obesity medications are anticipated to be helpful for post-surgical weight optimization given their efficacy in the non-surgical population.

Keywords: anti-obesity medications; bariatric (weight loss) surgery; obesity; obesity pharmacotherapy; weight regain after bariatric surgery.

MeSH terms

  • Anti-Obesity Agents* / therapeutic use
  • Bariatric Surgery*
  • Humans
  • Obesity, Morbid* / drug therapy
  • Topiramate / therapeutic use
  • Weight Gain
  • Weight Loss

Substances

  • Topiramate
  • Anti-Obesity Agents